Amplia Therapeutics Limited’s Post

🚨 Major breakthrough! The FDA has approved Zihera, a groundbreaking cancer-treating antibody developed by Vancouver-based biotech company Zymeworks! 🎉 This approval marks a huge milestone for treating metastatic HER2-positive biliary tract cancer—a rare and deadly form of GI cancer. This game-changing treatment offers hope where chemotherapy has failed, showing significant tumor shrinkage in clinical trials. 🧬💡 We’re celebrating this success and the incredible innovations coming out of Canada’s biotech sector. 🌍👏 Read More: https://lnkd.in/gygUvQw5 #PharmaInnovation #FDAApproval #CancerResearch #Zymeworks #Biotech #TorontoInstituteOfPharmaceuticalTechnology #MedicalBreakthroughs #Her2Positive #HealthTech

💡 Join Crown Bioscience for an upcoming webinar to explore the significant hurdle of cancer drug resistance, one of the greatest challenges in developing effective cancer therapeutics. 💊 Dr. Rajendra Kumari will discuss the evolving landscape of drug resistance, focusing on preclinical tools and strategies that can accelerate therapeutic discovery and provide actionable insights. Attendees will gain insights into specific models developed to study resistance to targeted therapies and immunotherapeutics, along with their features and practical applications for predicting clinical outcomes. ➡️ Learn more + register here: https://buff.ly/4eagwr7 #DrugDevelopment #DrugDiscovery #DrugResistance #Oncology #TherapeuticAreas #OncologyDrugDevelopment #CancerTherapy #PreClinical #CellAndGeneTherapies

𝐂𝐥𝐢𝐜𝐤 𝐡𝐞𝐫𝐞 𝐓𝐨 https://lnkd.in/euN7Z8i8 𝐠𝐞𝐭 𝐰𝐞𝐥𝐥-𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐫𝐞𝐩𝐨𝐫𝐭 The Mexico Antibody Drug Conjugates (ADC) Market is paving the way for groundbreaking advancements in oncology. Combining the precision of antibodies with the potency of cytotoxic drugs, ADCs are redefining cancer treatment by targeting cancer cells while sparing healthy tissue. With increasing investments in biotech R&D and growing adoption of personalized medicine, Mexico is emerging as a key player in the ADC landscape. 🚀 The future of oncology is here—focused, effective, and life-changing. To Get more:https://lnkd.in/dCyCfKzM #AntibodyDrugConjugates #OncologyInnovation #BiotechMexico #TargetedTherapies #PharmaTrends"

Top venture pick of the day: Hub71 based BioSapien: a local cancer treatment that can be attached to any tissue, with the drug injected directly into the tumor, resulting in minimal treatment side effects. Clinical protocol has been approved, clinical trials are on fast track, and manufacturing is starting. Backed by Meet the Drapers, Certara, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, UC San Diego, Vanderbilt University, SOSV, Hikma Pharmaceuticals, MicroVentures, National Science Foundation (NSF), Techstars. Khatija A. Sonia Ramamoorthy Joseph Borrello Martin Krusin Janet S Lee, PhD Agnes Westelinck David Jacobson-Kram Julie Bullock Abhishek Gupta Jedd Wolchok

Today on #WorldCancerResearchDay, we proudly stand with the global scientific community to underscore the critical role that research plays in improving cancer survival rates and enhancing the quality of life for patients and their families. At Zymeworks, we are deeply committed to the belief that continued research, innovation, and scientific advancement can profoundly impact the lives of cancer patients. As we advance our pipeline of multifunctional therapeutics, we honor our exceptional team of researchers, experts, and partners who are dedicated to harnessing the potential of antibody-drug conjugates (ADCs) and multispecific antibody therapeutics (MSATs) to address high unmet needs in the treatment of difficult-to-treat cancers. Together, we are driving innovation within #cancerresearch and remain unwavering in our commitment to making a meaningful difference. #AntibodyDrugConjugates #MultifunctionalTherapeutics #Biotech #DrugDevelopment #DrugDiscovery #CancerAwareness #Oncology #ResearchandDevelopment

Antibody-drug conjugates (ADCs) have emerged as a revolutionary approach to cancer treatment, enabling the targeted delivery of cytotoxic drugs to cancer cells while minimizing systemic toxicity. The global ADC market is witnessing remarkable growth, fueled by advancements in linker technologies, extensive research and development efforts, and the rising global incidence of cancer. In Taiwan, several companies are actively engaged in the development and manufacturing of ADCs, contributing significantly to the global oncology landscape. Download our FREE eBook: 𝐀 𝐋𝐨𝐨𝐤 𝐚𝐭 𝐓𝐚𝐢𝐰𝐚𝐧'𝐬 𝐆𝐫𝐨𝐰𝐢𝐧𝐠 𝐀𝐃𝐂 𝐏𝐢𝐩𝐞𝐥𝐢𝐧𝐞 𝐚𝐧𝐝 𝐋𝐞𝐚𝐝𝐢𝐧𝐠 𝐁𝐢𝐨𝐩𝐡𝐚𝐫𝐦𝐚 for more insights. DOWNLOAD HERE: https://lnkd.in/gDEb2HSH #imagineyourimpact #antibodydrugconjugates #ADC2025

Dallas-Based Lantern Pharma Leverages AI to Combat the Rising Threat of Lung Cancer in Non-Smokers : #news - Lung cancer, traditionally linked to smoking, is increasingly affecting individuals who have never smoked. Recent studies indicate that 15% to 25% of lung cancer diagnoses occur in never-smokers, with certain populations experiencing even higher rates. Lantern Pharma, a biotech company leveraging artificial intelligence (AI) to innovate cancer treatment and accelerate oncology drug discovery, has shared encouraging preliminary results from its ongoing Phase 2 HARMONIC™ clinical trial. MEDPULSE AI Read More ▶️ https://buff.ly/3B7iv0X 💡 #laternpharma #lungcancer #MedPulseAI #AIinHealthcare #AIinMedicine

𝗞𝗮𝗽𝗮𝗱𝗶 𝗮𝗻𝗱 𝗡𝗲𝘅𝘁 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗧𝗲𝗮𝗺 𝗨𝗽 𝗳𝗼𝗿 𝗦𝗶𝘅 𝗣𝗵𝗮𝘀𝗲 𝟭 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹𝘀 Exciting news! Next Oncology and Oncobay have joined forces to launch a series of groundbreaking Phase 1 clinical trials. Together, we are pushing the boundaries of cancer treatment! These trials will focus on evaluating novel immuno-oncology therapies designed to unleash the immune system's power against cancer. By combining our expertise, we aim to develop safer and more effective treatments for patients battling this relentless disease. Read the full press-release here: https://lnkd.in/dNhYazmU #CancerResearch #ImmunoOncology #ClinicalTrials #Collaboration #pressrelease #article #oncology #Kapadi #clinicaltrials #clinicalresearch #pharma #biotech

CDMO News - NorthStar Medical Radioisotopes, LLC will supply Ariceum Therapeutics with high-purity Actinium-225 (Ac-225) for developing targeted cancer therapies. Ariceum’s satoreotide will use Ac-225 to combat aggressive cancers like SCLC and pancreatic cancer. Read more about it at PharmaSource - https://lnkd.in/gzDGFUdE #CDMO #CancerTherapy #Radiopharmaceuticals #Ac225 #Biotech #Partnership #Innovation Jason Vinyard Kevin Staton

Immunotherapies have transformed cancer treatment, but considerable challenges remain. At Mural Oncology, we are using our advanced protein engineering capabilities to broaden the potential and reach of cytokine-based immunotherapies for people with cancer. Our lead candidate, nemvaleukin, is an investigational, engineered interleukin-2 (IL-2) cytokine designed to capture and expand the therapeutic benefits of high-dose native IL-2 while mitigating the cytokine’s hallmark toxicities. It is currently in two potentially registrational trials reading out next year. Discover our pipeline and learn about the clinical trials evaluating nemvaleukin: https://bit.ly/49hUu3c #biotechnology #oncology #drugdevelopment